T1	intervention 11 24	Ginkgo biloba
T2	condition 47 89	chemotherapy-related cognitive dysfunction
T3	eligibility 561 653	Previously chemotherapy na√Øve women about to receive adjuvant chemotherapy for breast cancer
T4	control 712 719	placebo
T5	outcome-Measure 926 966	High Sensitivity Cognitive Screen (HSCS)
T6	outcome-Measure 1003 1035	Trail Making Tests (TMT) A and B
T7	outcome-Measure 1037 1080	Subjective assessment of cognitive function
T8	outcome-Measure 1165 1194	Profile of Mood States (POMS)
T9	duration 1286 1295	24 months
T10	No-of-participants 1610 1635	One hundred and sixty-six
T11	outcome 1693 1711	differences in AUC
T12	outcome 1864 1889	differences in TMT A or B
T13	outcome 1909 1938	Perceived cognitive functions
T14	outcome 2114 2159	self-reported cognition and cognitive testing
T15	outcome 2193 2203	toxicities
